CSMYF (COSMOS Pharmaceutical) Operating Income: $276 Mil (TTM As of Feb. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

CSMYF COSMOS Pharmaceutical Corp CSMYF
93 GF Score
Price $37.06
GF Value $50.48
Valuation Modestly Undervalued
! 2 Warning Signs
View Full Analysis

What is COSMOS Pharmaceutical Operating Income?

COSMOS Pharmaceutical CSMYF 93 Operating Income is $276 Mil as of Feb. 2026. GuruFocus rates CSMYF with a GF Score™ of 93/100 and a GF Value™ of $50.48 (Modestly Undervalued). The stock has 2 warning signs investors should review.

COSMOS Pharmaceutical's Operating Income for the three months ended in Feb. 2026 was $73 Mil. Its Operating Income for the trailing twelve months (TTM) ended in Feb. 2026 was $276 Mil.

Operating Margin % is calculated as Operating Income divided by its Revenue. COSMOS Pharmaceutical's Operating Income for the three months ended in Feb. 2026 was $73 Mil. COSMOS Pharmaceutical's Revenue for the three months ended in Feb. 2026 was $1,761 Mil. Therefore, COSMOS Pharmaceutical's Operating Margin % for the quarter that ended in Feb. 2026 was 4.15%.

Warning Sign:

COSMOS Pharmaceutical Corp operating margin has been in a 5-year decline. The average rate of decline per year is -3.9%.

COSMOS Pharmaceutical's 5-Year average Growth Rate for Operating Margin % was -3.90% per year.

Operating Income or EBIT is linked to Return on Capital for both regular definition and Joel Greenblatt's definition. COSMOS Pharmaceutical's annualized ROC % for the quarter that ended in Feb. 2026 was 7.19%. COSMOS Pharmaceutical's annualized ROC (Joel Greenblatt) % for the quarter that ended in Feb. 2026 was 12.85%.


COSMOS Pharmaceutical  (OTCPK:CSMYF) Operating Income Explanation

1. Operating Income or EBIT is linked to Return on Capital for both regular definition and Joel Greenblatt's definition.

COSMOS Pharmaceutical's annualized ROC % for the quarter that ended in Feb. 2026 is calculated as:

ROC % (Q: Feb. 2026 )
=NOPAT/Average Invested Capital
=Operating Income * ( 1 - Tax Rate % )/( (Invested Capital (Q: Nov. 2025 ) + Invested Capital (Q: Feb. 2026 ))/ count )
=292.584 * ( 1 - 32.26% )/( (2665.703 + 2846.379)/ 2 )
=198.1964016/2756.041
=7.19 %

where

Invested Capital(Q: Nov. 2025 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=3498.39 - 1252.692 - ( 278.72 - max(0, 1477.739 - 1057.734+278.72))
=2665.703

Invested Capital(Q: Feb. 2026 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=3525.089 - 1183.102 - ( 199.102 - max(0, 1479.282 - 974.89+199.102))
=2846.379

Note: The Operating Income data used here is four times the quarterly (Feb. 2026) data.

2. Joel Greenblatt's definition of Return on Capital:

COSMOS Pharmaceutical's annualized ROC (Joel Greenblatt) % for the quarter that ended in Feb. 2026 is calculated as:

ROC (Joel Greenblatt) %(Q: Feb. 2026 )
=EBIT/Average of (Net fixed Assets + Net Working Capital)
=EBIT/Average of (Property, Plant and Equipment+Net Working Capital)
     Q: Nov. 2025  Q: Feb. 2026
=EBIT/( ( (Property, Plant and Equipment + Net Working Capital) + (Property, Plant and Equipment + Net Working Capital) )/ count )
=311.152/( ( (2368.444 + max(-664.034, 0)) + (2475.622 + max(-591.426, 0)) )/ 2 )
=311.152/( ( 2368.444 + 2475.622 )/ 2 )
=311.152/2422.033
=12.85 %

where Working Capital is:

Working Capital(Q: Nov. 2025 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(5.221 + 643.137 + 130.656) - (1252.692 + 0 + 190.356)
=-664.034

Working Capital(Q: Feb. 2026 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(5.164 + 640.857 + 129.767) - (1183.102 + 0 + 184.112)
=-591.426

When net working capital is negative, 0 is used.

Note: The EBIT data used here is four times the quarterly (Feb. 2026) EBIT data.

3. Operating Income is also linked to Operating Margin %:

COSMOS Pharmaceutical's Operating Margin % for the quarter that ended in Feb. 2026 is calculated as:

Operating Margin %=Operating Income (Q: Feb. 2026 )/Revenue (Q: Feb. 2026 )
=73.146/1761.458
=4.15 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

4. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Operating Income growth rate using Operating Income per share data.


Be Aware

Compared with a company's EBITDA margin, Operating Margin can be manipulated by adjusting the rate of depreciation, depletion and amortization (DDA).

If a company is facing competition, its Operating Margin may decline. Often the Operating Margin declines well before the company's revenue or even profit decline. Therefore, Operating Margin is a very important indicator of whether the company is facing problems.

For instance, by 2012, Nokia (NOK)'s problems were well known and its stock had lost more than 90% of its market value since 2007. But Nokia's Operating Margin had already been in decline since 2002, although its earnings per share were still rising. Investors who paid attention to Operating Margin would have avoided this huge loss. The same can be said for Research-in-Motion (RIMM).

Therefore, Operating Margin is a very important screening filter for GuruFocus. GuruFocus's Buffett-Munger screener requires that the profit margin is either consistent or expanding. The Model Portfolio of the Buffett-Munger screener has outperformed the market every year since inception in 2009.


COSMOS Pharmaceutical Operating Income Related Terms


COSMOS Pharmaceutical Operating Income Historical Data

* Premium members only.

The historical data trend for COSMOS Pharmaceutical's Operating Income can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

COSMOS Pharmaceutical Operating Income Chart

COSMOS Pharmaceutical Annual Data
Trend May17 May18 May19 May20 May21 May22 May23 May24 May25 May26
Operating Income
Get a 7-Day Free Trial Premium Member Only Premium Member Only 231.25 219.83 202.10 278.89 267.80

COSMOS Pharmaceutical Quarterly Data
Aug21 Nov21 Feb22 May22 Aug22 Nov22 Feb23 May23 Aug23 Nov23 Feb24 May24 Aug24 Nov24 Feb25 May25 Aug25 Nov25 Feb26 May26
Operating Income Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 60.58 78.96 58.22 73.15 65.32
CSMYF
93GF Score
COSMOS Pharmaceutical Corp CSMYF
Operating Income is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

COSMOS Pharmaceutical Operating Income Calculation

Operating Income, is the profit a company earned through operations. All expenses, including cash expenses such as cost of goods sold (COGS), research & development, wages, and non-cash expenses, such as depreciation, depletion and amortization, have been deducted from the sales.

Operating Income for the trailing twelve months (TTM) ended in Feb. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $276 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Operating Income →
What does a Operating Income of $276 Mil mean?
COSMOS Pharmaceutical (CSMYF) has a Operating Income of $276 Mil as of Feb. 2026. Operating Income equals sales less all operating expenses. It is linked to EBIT. View historical data on COSMOS Pharmaceutical and its competitors.
Is COSMOS Pharmaceutical's Operating Income too high?
COSMOS Pharmaceutical's current Operating Income is $276 Mil. Overall, COSMOS Pharmaceutical has a GF Score™ of 93/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does COSMOS Pharmaceutical's Operating Income compare to competitors?
COSMOS Pharmaceutical's Operating Income of $276 Mil can be compared against companies in the Healthcare Providers & Services industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Operating Income for a Healthcare Providers & Services company?
A good Operating Income depends on the Healthcare Providers & Services industry context. However, Operating Income should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Operating Income mean?
A high Operating Income can signal that a stock is expensive relative to its fundamentals. Operating Income equals sales less all operating expenses. It is linked to EBIT. View historical data on COSMOS Pharmaceutical and its competitors. COSMOS Pharmaceutical's current Operating Income is $276 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is COSMOS Pharmaceutical stock overvalued right now?
Based on GuruFocus' analysis, COSMOS Pharmaceutical (CSMYF) is currently considered Modestly Undervalued. The stock's GF Value™ is $50.48, compared to a current price of $37.06 — trading 26.6% below its estimated fair value. The current Operating Income is $276 Mil. COSMOS Pharmaceutical's overall GF Score™ is 93/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Operating Income calculated?
Operating Income is calculated from a company's financial statements. For COSMOS Pharmaceutical (CSMYF), the current Operating Income is $276 Mil as of Feb. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is COSMOS Pharmaceutical (CSMYF) Overvalued in 2026?

Based on GuruFocus' analysis, COSMOS Pharmaceutical stock appears to be undervalued. The current stock price of $37.06 is trading 26.6% below its estimated GF Value™ of $50.48. GuruFocus considers COSMOS Pharmaceutical to be Modestly Undervalued.

Key valuation signals for CSMYF:

  • Operating Income: $276 Mil
  • GF Value™: $50.48 vs. price of $37.06 (26.6% below fair value)
  • GF Score™: 93/100 with 2 warning signs

No single metric tells the full story. See the CSMYF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


COSMOS Pharmaceutical Business Description

Other Exchanges 3349:Japan
Address 10-1 Hakataeki Higashi 2-chome, 4th floor, JR Hakata Station East NS Building S, Hakata-ku, Fukuoka Prefecture, Fukuoka, JPN, 812-0013
COSMOS Pharmaceutical Corp manages retail drugstores in Japan. The company emphasizes convenience regarding its product selection, which includes medical products, health and beauty aids, personal-care items, discount cosmetics, household items, food and beverages, greeting cards, seasonal merchandise, alcoholic beverages, tobacco, insect repellent, and miscellaneous everyday consumables. The majority of the company's revenue is derived from common grocery sales. It also operates a private grocery brand called ON 365.
93GF Score

Get the complete analysis for CSMYF

Operating Income is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$37.06
Price
$50.48
GF Value